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Background: The relationship between homocysteine (Hcy) and diabetic retinopathy (DR) remains unclear to date.
Therefore, a systematic review and meta-analysis was performed on the relationship between Hcy level and DR.
Methods: Studies were identified by searching PubMed, Embase, and Web of Science databases until 5 May, 2014.
Results: A total of 31 studies involving 6,394 participants were included in the meta-analysis. After pooling the data
from each included study, the blood Hcy concentration in the DR group was observed to be higher than that in
the control group [WMD = 2.55; 95% confidence interval (CI), 1.70–3.40], and diabetes mellitus (DM) patients with
hyperhomocysteinemia were at a risk for DR [odds ratio (OR) = 1.93; 95% CI, 1.46–2.53]. Considering the different
DM types, hyperhomocysteinemia in T1DM (OR = 1.83, 95% CI, 1.28–2.62) was associated with DR rather than in
T2DM (OR = 1.59, 95% CI, 0.72–3.51). Considerable statistical heterogeneity in the overall summary estimates was
partly explained by the geographical differences.
Conclusions: Results from this current meta-analysis indicate that hyperhomocysteinemia is a risk factor for DR,
especially proliferative DR. Differences between geographical regions were observed in the relationship between
hyperhomocysteinemia with T1DM risk. Given the heterogeneous results, the relationship between high Hcy and
DR needs further investigation.
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Diabetic retinopathy (DR), a common complication of
diabetes, is the leading cause of low vision and blindness
worldwide [1]. To date, no effective treatment has been
found. Therefore, finding new risk factors and biomarkers
to prevent the progression of DR is important. A number
of risk factors are associated with the incidence of DR,
such as blood pressure, blood glucose, glycosylated
hemoglobin, blood urea nitrogen, creatinine, and β2-
microglobulin. However, the risk factors for DR are
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unless otherwise stated.Homocysteine (Hcy) is a sulfur-containing amino acid
formed by the demethylation of methionine; it is an emer-
ging risk factor for diabetic nephropathy and cardiovascu-
lar disease that has gradually elicited the interest of
researchers [2]. These researchers found that the level of
Hcy is related to DR, especially proliferative DR [3,4].
However, studies on the relationship between Hcy and
DR have reported inconsistent results, and the role of
Hcy in the development of DR is not clearly elucidated.
Several studies have shown relationships between the
blood Hcy level and the prevalence of DR [5,6]. Plasma
total Hcy concentration may be a useful biomarker for
increased risk of DR in people with type 2 diabetes
mellitus (T2DM) [7] and a complication risk indicator in
type 1 diabetes mellitus (T1DM) [3]. Moderate hyperho-
mocysteinemia has been described in T1DM, which mayThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ylenetetrahydrofolate reductase (MTHFR) gene [8,9]. On
the other hand, other studies did not find any relationship
between plasma Hcy and different grades of DR on
adults with T1DM, except when concomitant nephropa-
thy existed [10,11].
Given the absence of uniform research standards and
inconsistency in research results, a meta-analysis of pro-
spective studies on the relationship between Hcy and
DR was conducted.
This meta-analysis mainly focused on the following
objectives: (1) to review and summarize the epidemiologic
evidence on the relationship between hyperhomocysteine-
mia and risk of DR and (2) to quantify the mechanism of
hyperhomocysteinemia and DM relationship according to
study characteristics.Methods
Search strategy
The meta-analysis was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis guidelines [12].Study selection
We searched PubMed, Embase, and Web of Science to
retrieve related studies published before May, 2014.
Literature search was performed using keywords “homo-
cysteine,” “hyperhomocysteinemia,” “Hcy,” and “homocys-
teic acid” in combination with “diabetic retinopathy” and
“diabetic retinitis.” Moreover, the citations of related articles
were detected for additional publications. No language or
date limitations were set. Corresponding authors of the re-
trieved articles were contacted for additional information.Inclusion criteria
Studies that met the following inclusion criteria were
included in this meta-analysis: (1) comparative studies; (2)
reported either the prevalence in hyperhomocysteinemia
patients and the controls or the concentrations of Hcy in
DR and the controls; and (3) provided the value of mean
with 95% confidence intervals (CIs), standard errors or
sufficient data to calculate them.Exclusion criteria
Studies that met the following inclusion criteria were
excluded in this meta-analysis: (1) not for DR research;
(2) studies with small sample size (less than 40 cases or
control group) and low quality (NOS, less than 6 points)
(3) duplicate of previous publication; and articles without
available data; (4) the plasma Hcy levels of studies are
influenced seriously by pathological factors.Data extraction
Data were independently extracted from each included
article by two reviewers (C. Xu and Y. Wu), and all
disagreements on eligibility during the extraction were
discussed and resolved by the reviewers. The first author,
country, year of publication, number of both case and
control groups, blood components used for the test, DM
type, definition of hyperhomocysteinemia, and matching
factors were extracted.
Assessment of methodology quality
The Newcastle–Ottawa scale (NOS) [13] was adopted
for assessing the quality of the included retrospective
observational studies. The maximal NOS score was 9
points, and studies ≥6 points were considered to be of
relatively higher quality.
Statistical analysis
This meta-analysis was conducted using the Stata software
package (version 11.0; Stata Corp., College Station, TX). A
random-effect method was conducted to pool the results
together [14]. The pooled odds ratios (ORs) and weighted
mean difference (WMD) were measured with 95% CIs.
Both the ORs and WMD were considered statistically
significant. The subgroup analyses were performed based
on DM type, site, blood component, and study design.
Both the χ2 and I2 tests were used to evaluate the statis-
tical heterogeneity among studies, and the heterogeneity
was considered statistical when P < 0.1 and I2 ≥ 50%. Meta-
regression method was used to evaluate the source of
heterogeneity.
The sensitivity analysis evaluated the robustness of the
results in this study. Two different methods were per-
formed to conduct this analysis. First, the articles were
excluded one by one, and then a meta-analysis was again
conducted. Second, studies with small sample size (less
than 40 participants in either case or control group) and
low quality (NOS, less than 6 points) were excluded. To
evaluate the potential publication bias, both the funnel
plot and the Egger test were performed [15,16].
Results
Literature search
Of the 299 articles (72 from PubMed, 147 from Embase,
and 80 from Web of Science) identified from database
searches, 132 duplicates were excluded. After reviewing
the titles and abstract of the 167 remaining articles, 114
articles were excluded and 53 full-text articles were
assessed for eligibility. A total of 24 articles (four from
duplicated data sources and 20 without available data)
were excluded. Moreover, two studies were identified
from reference lists. Thirty-one articles were included in
this meta-analysis [2-11,17-37], in which nine reported
the relationship between hyperhomocysteinemia and risk
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NDR (six studies reported both results).Characteristics and baseline of the included studies
Up to 6394 individuals were included in this meta-analysis.
A total of 609 cases and 238 controls comprised the com-
parison between the risk of DR in hyperhomocysteinemia
and control groups, and 2070 cases and 3477 controls
comprised the comparison between the concentrations of
Hcy in DR and NDR groups. The definitions of hyperho-
mocysteinemia were different in each study, and four of
nine studies used 15 μmol/l in the plasma as cut-off.
Although the definitions were not the same, no significant
differences existed in the definitions. Both plasma and
serum were used for the measurement of the concentra-
tions of Hcy in most studies. All of the included articles
were retrospective case–control studies. Of the 31 in-
cluded studies, 4 were conducted in the United States,
11 in Asia, 14 in Europe, and 2 in Oceania. Age and
gender were matched in most of the studies. Several
studies displayed other comparable factors. Tables 1
and 2 show the characteristics and baselines of the
included studies.Quality assessment
NOS was used to evaluate the methodological quality of
each study because all of the included articles were
retrospective case–control studies. Among the 31 studies,
six were less than 6 points, and the mean NOS score was
6.45 ± 1.21 points. The lowest and the highest scales
were 4 points in two studies and 8 points in six studies,
respectively.Table 1 Characteristics of the studies on the relationship betw
retinopathy




Golbahar et al. 2008 [17] Bahrain 124/130 2
Vaccaro et al , 1997 [8] Japan 11/14 1
Hofmann et al., 1998 [18] France 26/49 1
Hoogeveen et al., 2000 [5] Netherlands 534/91 2
Buysschaert et al., 2000 [19] Belgium 38/84 1
Agullo-Ortuno et al., 2002 [3] Spain 18/71 1, 2
Goldstein et al., 2004 [4] Israel 84/251 NA
de Luis et al., 2005 [20] Spain 22/133 2
Satyanarayana et al., 2011 [21] US 141/159 2
NA: not available; DM: diabetes mellitus; F: female; M: male; Hcy: homocysteine.
†Study quality is evaluated by Newcastle-Ottowa Scale (1–9 stars).
*The matching factors are: (1) age, (2) gender, (3) diabetes duration, (4) diabetes co
(9) plasma cholesterol, (10) triglyceride, (11) low densitv lipoprotein, (12) high densEfficacy analysis
Main results
Figure 1 presents the main results of this current meta-
analysis. Patients with hyperhomocysteinemia were at
higher risk of developing DR compared with the control
group (OR, 1.93; 95% CI, 1.46 to 2.53). The interstudy
heterogeneity was not significant (I2 = 26.9%, P = 0.205).
A higher concentration of Hcy in the blood was observed
in the DR group (WMD, 2.55; 95% CI, 1.70 to 3.40). How-
ever, a significant heterogeneity was also detected in the
comparison (I2 = 98.8%, P < 0.001).
Subgroup analysis
Subgroup analysis was conducted by DM type, geographic
site, blood components, and study designs (Table 3). In
the different DM types, T2DM patients with hyperhomo-
cysteinemia did not show higher risk of developing DR
(OR, 1.59; 95% CI, 0.72 to 3.51). However, in both T1DM
and mixed-type DM groups, higher incidence rates of
DR were detected in the hyperhomocysteinemia group
(T1DM: OR, 1.83; 95% CI, 1.28 to 2.62; Mixed: OR,
1.93; 95% CI, 1.46 to 2.53). In all of the three different
DM type groups, the concentration of Hcy was higher
in DR groups (T1DM: WMD, 2.5; 95% CI, 1.04 to 3.97;
T2DM: WMD, 2.85; 95% CI, 1.45 to 4.25; Mixed: WMD,
1.68; 95% CI, 0.01 to 3.35).
In the United States and Asia, a higher incidence rate
of DR was detected in the hyperhomocysteinemia group
(US: OR, 1.9; 95% CI, 1.24 to 2.93; Asia: OR, 2.36; 95%
CI, 1.46 to 3.81). However, in Europe, the incidence rate
of DR was not higher in the hyperhomocysteinemia group
compared with the control group (OR, 1.45; 95% CI, 0.95







Plasma F: Hcy > 15 μmol/l; M:
Hcy > 12 μmol/l
8 1, 2, 3, 4, 7, 12, 13
Plasma ≥10 μmol/ 6 1, 2, 6, 8, 9, 13
Plasma Preload > 15.8 μmol/l or
Postload >31.1 μmol/l
8 1, 2, 3, 4, 6, 7, 9
serum >16 μmol/l 7 1, 2, 7, 8, 9
Plasma >15 μmol/l 7 1, 2, 3, 5, 6, 10, 11, 12
Plasma F >13.9 μmol/l,
M >15.6 μmol/l
5 9, 10, 11, 12
Plasma >15 μmol/l 7 1, 6, 14
Plasma ≥ 15 μmol/l 6 1, 6, 7, 8, 9
Plasma > 12 μmol/l 7 1, 5, 9, 11
ntrol, (5) hypoglycemia medication, (6) blood pressure, (7) BMI, (8) creatinine,
itv lipoprotein, (13) smoking status, (14) other complications.
Table 2 Characteristics of the studies on the comparison between the concentrations of homocysteine in the DR and
NDR group










Chen, 2010 [22] China 88/95 2 DR/normal or DM Plasma 6 1 2
Golbahar et al. , 2008 [17] Bahrain 124/130 2 DR/DM Plasma 8 1, 2, 3, 7, 8, 9, 10, 11, 12, 13
Lim et al., 2012 [23] Malaysia 20/21 2 PDR/Normal Plasma 5 1, 2
Hultberg et al., 1991 [24] Sweden. 67/46 1 DR/Normal Plasma 6 1, 2, 6, 13
Chico et al., 1998 [2] Spain 71/62 1,2 DR/DM Plasma 8 1, 2, 7, 14
Smulders et al., 1999 [25] Netherlands 66/71 2 DR/DM Plasma 7 2
Stabler et al., 1999 [26] US 218/223 2 DR/DM Plasma 6 1, 2, 14
Agardh et al., 2000 [10] Sweden. 25/24 1 DR/DM Plasma 7 1, 2, 3, 5, 6, 7
Vaccaro et al., 2000 [9] Italy 30/34 NA DR/DM Plasma 7 1, 2, 6, 13
Chiarelli et al., 2000 [27] US 141/117 1 DR/Normal or DM Plasma 8 1, 2, 3, 5
Buysschaert et al., 2001 [28] France 24/47 1 DR/DM Plasma 5 1, 2, 5
Agullo-Ortuno et al., 2002 [3] Spain 18/71 1 DR/DM Plasma 6 9, 10, 11, 12
Yang et al., 2002 [29] China 16/58 2 DR/Normal or DM Plasma 7 1, 2, 6, 7
Abdella et al., 2002 [30] Kuwait 145/213 2 DR/DM Plasma 6 1, 3, 5, 13
Looker et al., 2003 [31] US 102/279 2 DR/DM Serum 8 2, 4, 5, 6, 13
Saeed et al., 2004 [11] UK 25/23 1 NPDR/DM Serum 7 1, 2, 3, 6, 7, 13
Goldstein et al., 2004 [4] Israel 117/218 NA DR/Normal or DM Plasma 6 1, 6, 14
de Luis et al., 2005 [20] Spain 22/133 2 DR/DM Plasma 7 1, 6, 7, 8, 9
García-Unzueta et al., 2005 [32] Spain 38/117 1 DR/DM Serum 4 NA
Yücel I, 2004[33] Turkey 20/30 2 PDR/Normal Plasma 4 1, 2
Huang et al., 2006 [6] China 91/370 2 DR/Normal or DM Plasma 7 1, 2, 9, 11
Brazionis et al., 2008 [7] Australia 48/120 2 DR/DM Plasma 8 1, 2, 4, 6, 10, 12, 13
Aydin E, 2008 [34] Turkey 39/35 2 DR/Normal or DM Plasma 4 1, 2
Aydemir et al., 2008 [35] Turkey 20/12 2 PDR/Normal Plasma 5 1
Nguyen et al., 2009 [36] Australia 278/743 NA DR/DM Plasma 7 1, 2, 7, 9, 10, 13
Satyanarayana et al., 2011 [21] US 150/150 2 DR/Normal or DM Plasma 7 1, 5, 9, 11
Cho, 2011 [37] Korea 67/35 2 DR/DM Plasma 6 1, 6, 7, 11, 12
NA: not available; DM: diabetes mellitus; DR: diabetic retinopathy; PDR: proliferative diabetic retinopathy.
†Study quality is evaluated by Newcastle-Ottowa Scale (1–9 stars).
*The matching factors are: (1) age, (2) gender, (3) diabetes duration, (4) diabetes control, (5) hypoglycemia medication, (6) blood pressure, (7) BMI, (8) creatinine,
(9) plasma cholesterol, (10) triglyceride, (11) low densitv lipoprotein, (12) high densitv lipoprotein, (13) smoking status, (14) other complications.
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group (Asia: WMD, 3.43; 95% CI, 2.59 to 4.28; Europe:
WMD, 1.68; 95% CI, 0.83 to 2.52). However, the concentra-
tions of Hcy in the DR groups were not significantly higher
in the US and Oceania (US: WMD, 3.03; 95% CI, −0.02 to
6.08; Oceania: OR, 0.68; 95% CI, −0.49 to 6.08).
Four different study designs, namely, DR vs. normal,
DR vs. DM, non-proliferative diabetic retinopathy (NPDR)
vs. control, and PDR vs. control, were used in the sub-
group analysis. A higher incidence rate in hyperhomo-
cysteinemia was detected in all of the subgroups, and a
higher concentration of Hcy was detected in the DR
group. No inverse results were detected in the subgroup
analysis compared with the main results.The incidence of DR was compared in the two groups
(high Hcy and control). Only the subgroup analysis be-
tween the DR and the normal group was significantly
heterogeneous (I2 = 90.9, P < 0.01). However, most sub-
group analyses exhibited significant heterogeneity com-
pared with the Hcy concentrations in DR and NDR. No
significant heterogeneity was observed between the DR
and the NDR groups, whereas the comparison of Hcy
serum was significantly heterogeneous (I2 = 51.5, P = 0.13).
Heterogeneity, sensitivity analysis, and publication bias
Several outcomes were heterogeneous in this meta-
analysis, and the subgroup analysis did not succeed
in detecting the source of heterogeneity. In addition,
Figure 1 Forest plot of relationship between homocysteine level and diabetic retinopathy. (A) The concentration of Hcy was higher in DR
groups than the control group (WMD, 2.55; 95% CI, 1.70 to3.40) (B) Diabetes mellitus (DM) patients with hyperhomocysteinemia were at a risk for
DR [odds ratio (OR) = 1.93; 95% CI, 1.46–2.53].
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heterogeneity were detected.
After dropping each study one by one from the included
studies, no significant different results were observed. A
meta-analysis was conducted after excluding the studies
with small sample size (less than 40 participants in either
case or control group) and low quality (NOS, less than 6
points). After excluding five studies, a significant relation-
ship was observed between hyperhomocysteinemia and
risk of DR (OR, 2.16; 95%, 1.63 to 2.85). Moreover, after
excluding 12 studies, the concentration of Hcy in the DR
group was still higher than that in the control group
(WMD, 2.16; 95% CI, 1.12 to 3.40).
Both the funnel plot (Figure 2) and the Egger test
showed that no potential publication bias existed in the
comparison between the incidence rate of the hyperho-
mocysteinemia group and the control (P = 0.07) groupand the comparison between the concentration of Hcy
in DR and control group (P = 0.63).
Discussion and conclusions
A large number of studies focused on the relationship
between Hcy and retinopathy, but their results were incon-
sistent. Studies on T1DM reported positive relationships
between DR and Hcy [38,39]. Hcy significantly increased in
DM patients, and Hcy may be related to longer diabetic
duration and DR [6]. Elevated Hcy was also related to
increased risk for proliferative retinopathy [31,34]. A
high prevalence of retinopathy was found in patients
with T2DM who had fasting Hcy concentrations greater
than 15 μmol/l [3,5]. Hcy may be a predictor of retinopathy
in T2DM [7,9,37].
In some studies, no significant correlations existed be-
tween plasma Hcy and different grades of DR in patients
Table 3 Relationship between hyperhomocysteinemia and risk of diabetic retinopathy, and the concentrations of hcy
between the DR and NDR groups by subgroup analysis
Hyperhomocysyeinemia and risk of diabetic retinopathy Homocysteine in DR and NDR
Factor No. of
studies
OR 95% CI Heterogeneity No. of
studies
WMD 95% CI Heterogeneity
P I2 (%) P I2 (%)
DM type
T1D 3 1.83 1.28 to 2.62 0.21 33.6 7 2.5 1.04 to 3.97 0.00 94.0
T2D 4 1.59 0.72 to 3.51 0.19 39.7 16 2.85 1.45 to 4.25 0.00 99.2
Mixed 2 1.93 1.46 to 2.53 0.93 0.0 4 1.68 0.01 to 3.35 0.00 97.2
Site
Unitd Staes 1 1.9 1.24 to 2.93 - - 4 3.03 −0.02 to 6.08 0.00 85.0
Asia 4 2.36 1.46 to 3.81 0.15 44.3 11 3.43 2.59 to 4.28 0.00 88.6
Europe 4 1.45 0.95 to 2.20 0.57 0.0 10 1.68 0.83 to 2.52 0.00 85.0
Oceania - - - - - 2 0.68 −0.49 to 6.08 0.00 99.8
Blood
Plasma 8 2.01 1.49 to 2.72 0.20 29.0 24 2.81 2.04 to 3.57 0.00 97.3
Serum 1 1.45 0.79 to 2.67 - - 3 0.45 0.03 to 0.87 0.13 51.5
Study design
DR vs normal 3 3.71 0.94 to 14.72 0.0 90.9 11 5.21 3.50 to 6.92 0.00 99.2
DR vs DM 9 2.02 1.52 to 2.68 0.33 12.1 22 2.34 1.62 to 3.05 0.00 97.6
NPDR vs control 2 2.66 1.74 to 4.06 0.88 0.0 10 1.8 0.89 to 2.71 0.00 96.4
PDR vs control 2 2.84 1.75 to 4.61 0.98 0.0 12 4.53 3.16 to 5.90 0.00 91.6
-: no data; DM: diabetes mellitus; T1D: type 1 diabetes mellitus; T2D: type 2 diabetes mellitus; DR: diabetic retinopathy; PDR: proliferative diabetic retinopathy;
NPDR: nonproliferative diabetic retinopathy; hcy: homocysteinemia.
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was present [10,11,30,36]. Hyperhomocysteinemia is
probably caused by early nephropathy rather than a re-
sult of the diabetic process itself [2,11,40]. The reasons
for these inconsistencies may be due, in part, to differences
in the study sample (e.g., groups with different diabeticFigure 2 Funnel plot of the included studies. Funnel plot of the WMD vs
level and diabetic retinopathy.duration), study design, definitions of DR (e.g., clinical
versus photograph grading), and failure in some studies to
make adequate adjustments for traditional risk factors.
A comprehensive and quantitative summary was lacking
on the relationship between Hcy and DR. Therefore, a
meta-analysis was conducted to assess the relationshipthe standard error of the log WMD for studies evaluating homocysteine
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DR groups compared with the normal or DM patients,
Hcy concentration in the blood was higher than in the
control. These results are the same as those of the PDR
groups compared with the control, especially in Asia and
Europe. No significant differences were observed in
Australia and USA. These findings may be associated
with research heterogeneity or the district biases. The
different research methods and the sensitivity to detect
retinopathy by fundus photography or misclassification
of retinopathy may result in district bias.
Plasma Hcy levels are influenced by environmental
and genetic factors [41], as well as by age, sex, duration
of diabetes, smoking habits, body mass index, metabolic
control, creatinine clearance, impaired renal function,
vitamin status, and blood pressure [11,21,28,42]. The
kidney has an important function in maintaining Hcy
levels. The enzyme MTHFR is active in the kidney, and
impairment of renal function can lead to hyperhomo-
cysteinemia [11].
Many studies excluded serious pathology state of
research groups, and different research groups matched
for these factors, which could influence plasma Hcy
levels. Therefore, we believe that hyperhomocysteinemia
may be a potential risk factor for DR patients [31].
A higher incidence of DR exists in diabetic patients
with hyperhomocysteinemia. According to the different
DM types, a significant difference in T1DM group is
observed, whereas no significant difference is detected in
T2DM group. Given all the differences, the incidence ofFigure 3 Flow diagram showing the identification of relevant studies
133 uplicates and 114 unrelated articles were excluded. A total of 53 full-te
excluded from and 2 articles from reviewing the reference lists of the relat
this meta-analysis.DR in hyperhomocysteinemia cases is higher than in the
control, except in Europe. Although most relationships
are not significant, a high homocysteinemia is common in
the relationship with the incidence of DR, especially with
PDR (Table 3). To understand the significance of the results
in Table 3, heterogeneity and subgroup analyses were ana-
lyzed. In the comparison between the incidence of DR in
different levels of plasma Hcy groups, only the DR groups
compared with normal groups were significantly heteroge-
neous (I2 = 90.9, P < 0.01). This result may due to the differ-
ent study designs with different methodological qualities.
The pathogenesis of hyperhomocysteinemia in the
development of DR may accelerate cell injury (including
oxidative stress and impaired generation of nitric oxide)
and proliferate smooth muscle cells to alter vasomotor ac-
tivity [43,44]. Cell injury at the level of the retinal capillary
may contribute to the development of DR [8,18,45,46].
The relationship between PDR and plasma Hcy levels may
be related to C677T mutation in the gene coding for the
MTHFR [8,9,17,47].
A few studies demonstrated that vitreous hyperhomo-
cysteine is related to DR because of the loss of blood–
retinal barrier permeability. This result may augment
the diffusion of Hcy into the vitreous and the changes in
vascular permeability [35,48]. Therefore, an elevated
Hcy level in the vitreous may be important in the patho-
genesis of PDR [23].
Given the numerous factors influencing the devel-
opment and progression of DR, some of them remain
unknown. We believe that hyperhomocysteinemia isin the meta-analysis. The initial 299 articles were identified and after
xt articles were assessed for eligibility. Twenty-four articles were
ed articles were included. In final, 31 articles were included in
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ity of retinopathy independent of other risk factors [4].
The most significant conclusion that can be obtained
from the data in Figures 1, 2 and 3 is the influence of
concentration of plasma Hcy level on the incidence of
DR and the progression of this microvascular complica-
tion of the retina, particularly in T1DM in Asia and the
United States.
Some limitations of this meta-analysis are as follows.
First, the included studies are not randomized controlled
trials, and thus, may hold potential bias. Second, several
outcomes were quite heterogeneous in this meta-analysis,
and the subgroup analysis was not successful in detecting
the source of heterogeneity. Moreover, we cannot obtain a
possible threshold between the blood Hcy level and the
separate degrees of DR because of the limited number of
subjects with retinopathy and the different study designs.
The risk factors for DR are complicated by many as-
pects. Using Insulin may increase the risk of diabetic ret-
inopathy [49], However, hyperhomocysteinemia correlates
with insulin resistance and it could play a role in the
higher risk of cardiovascular disease in obesity [50]. Dia-
betic retinopathy (DR) was earlier recognized as a vascular
disease, but nowadays, it is considered as a neurovascular
disorder. hyperhomocysteinemia plays important role in
causation of retinal ganglionic cell apoptosis in diabetic
patients [51]. Moreover, gene–gene and gene–environ-
ment interactions should also be considered in future ana-
lysis.PPARγ2 Pro12Ala polymorphism is not a risk factor
for developing T2D diabetic nephropathy [52]. The associ-
ation of plasma Hcy level and MTHFR gene polymorph-
ism also be widely studied [53]. MTHFR polymorphism
is shown to be associated with lipid metabolism in
the elderly women [54].And this consistence to our
study that Hcy level is related to MTHFR (coded by
C667Tgene) polymorphism and may be the risk of
diabetic complications.
All these meta-analysis are very significant to show the
relationship between the different risk factors with dia-
betic retinopathy and other diabetic Complications.
But our meta show the relationship between Hcy and
different aspect of DR deeply.
Hcy may be a potential useful biomarker in assessing
the microvascular risk in diabetes, and hyperhomocystei-
nemia is a potential risk factor for DR, especially PDR.
This result may help DM patients in obtaining an instruct-
ive management to prevent the progression of DR because
the plasma Hcy level can be substantially lowered with
folic acid supplementation. High Hcy on DR will result in
increasing attention to the study of gene C667T poly-
morphism and related prevention and treatment methods.
In addition, considering the limitation of this study, larger
studies should be considered and conducted to validate
the current meta-analysis.Abbreviation
Hcy: Homocysteine; DR: Diabetic retinopathy.
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